MDACC Study No:2013-0629 ( NCT No: NCT01850004)
Title:Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
Principal Investigator:Jorge Cortes
Treatment Agent:Dasatinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn about the effects of
stopping dasatinib in patients with CP-CML who have achieved a CMR.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Dasatinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults